StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Gilead Sciences (GILD) Likely to Provide Remdesivir to only 1/3 of US Patients - RBC Capital
May 5, 2020 7:18 AM
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $88.00 price target on Gilead Sciences (NASDAQ: GILD) noting that ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments